Search
Propiolactone
go.drugbank.com/drugs/DB09348ApprovedWithdrawnPropiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical ins...
Rexin G
go.drugbank.com/drugs/DB16450InvestigationalIt is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
DLO6001
go.drugbank.com/drugs/DB05178ExperimentalDL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.
Benoxaprofen
go.drugbank.com/drugs/DB04812ApprovedWithdrawnThe holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalUCB-1184197
go.drugbank.com/drugs/DB05092InvestigationalCDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis. … CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple
LGD2941
go.drugbank.com/drugs/DB05234ExperimentalLGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
AVI-5126
go.drugbank.com/drugs/DB05726InvestigationalAVI-526 is an improved formulation of [AVI-4557], developed for use on Vein Grafts before use in Heart by-Pass Graft Surgery. … The drug was under investigation in clinical trial NCT00451256 (Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)).
NRP369
go.drugbank.com/drugs/DB06384ExperimentalNRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].
Inositol 1,3-bisphosphate
go.drugbank.com/drugs/DB02942ExperimentalIt is an experimental compound with no approved therapeutic indications. … The compound corresponds to the soluble headgroup of phosphatidylinositol 3-phosphate (PtdIns(3)P), an endosomal signaling lipid recognized by FYVE domains, and it has been used as a ligand in structural
Imidacloprid
go.drugbank.com/drugs/DB11421ExperimentalVet approvedImidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise
Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsSynonyms: 1-((6-chloro-3-Pyridyl)methyl)-N-nitro-2-imidazolidinimine, 1-((6-chloro-3-Pyridinyl)methyl)-N-nitro-2-imidazolidinimine